Subtopic Deep Dive
Second-Generation Tyrosine Kinase Inhibitors
Research Guide
What is Second-Generation Tyrosine Kinase Inhibitors?
Second-generation tyrosine kinase inhibitors (TKIs) are dasatinib and nilotinib, designed to overcome imatinib resistance in chronic myeloid leukemia (CML) by targeting BCR-ABL mutations with higher potency.
Dasatinib and nilotinib demonstrate superior molecular response rates and progression-free survival compared to first-generation imatinib in newly diagnosed and resistant CML patients. Key trials include DASISION for dasatinib (Cortes et al., 2016, 913 citations) and ENESTnd for nilotinib (Hochhaus et al., 2016, 838 citations). Over 20 phase III trials compare switching strategies and long-term outcomes.
Why It Matters
Second-generation TKIs enable frontline therapy optimization, reducing progression risk by 20-30% in imatinib-intolerant patients (Hochhaus et al., 2020). DASISION showed dasatinib achieving deeper MMR at 5 years (Cortes et al., 2016), guiding ELN recommendations for high-risk CML (Hochhaus et al., 2020, 1444 citations). Cardiovascular risk assessment integrates with TKI selection (Lyon et al., 2020), improving 10-year survival rates above 85%.
Key Research Challenges
BCR-ABL Mutation Resistance
T315I mutations resist both imatinib and second-generation TKIs, limiting options (Kantarjian et al., 2006). Ponatinib addresses this but carries vascular risks (Cortes et al., 2013, 1108 citations). Trials show 15-20% mutation prevalence in resistant cases.
Cardiovascular Toxicity Management
Nilotinib elevates QT prolongation and PAOD risks, requiring baseline assessments (Lyon et al., 2020, 708 citations). Dasatinib links to pleural effusions in 20% of patients (Cortes et al., 2016). ELN guidelines mandate monitoring (Hochhaus et al., 2020).
Optimal Switching Strategies
Deciding when to switch from imatinib remains contentious despite superior early responses with dasatinib/nilotinib (Hochhaus et al., 2016). Long-term data show persistent imatinib efficacy in 50% (Druker et al., 2006, 3454 citations). Risk stratification via Sokal score influences outcomes.
Essential Papers
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Brian Druker, François Guilhot, Stephen G. O’Brien et al. · 2006 · New England Journal of Medicine · 3.5K citations
After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. (ClinicalTrials.gov nu...
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Andreas Hochhaus, Michele Baccarani, Richard T. Silver et al. · 2020 · Leukemia · 1.4K citations
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Hagop M. Kantarjian, Francis J. Giles, Lydia Wunderle et al. · 2006 · New England Journal of Medicine · 1.3K citations
Nilotinib has a relatively favorable safety profile and is active in imatinib-resistant CML. (ClinicalTrials.gov number, NCT00109707 [ClinicalTrials.gov].).
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus, Richard A. Larson, François Guilhot et al. · 2017 · New England Journal of Medicine · 1.2K citations
Almost 11 years of follow-up showed that the efficacy of imatinib persisted over time and that long-term administration of imatinib was not associated with unacceptable cumulative or late toxic eff...
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz et al. · 2013 · New England Journal of Medicine · 1.1K citations
Ponatinib had significant antileukemic activity across categories of disease stage and mutation status. (Funded by Ariad Pharmaceuticals and others; PACE ClinicalTrials.gov number, NCT01207440 .).
Kinase drug discovery 20 years after imatinib: progress and future directions
Philip Cohen, Darren A.E. Cross, Pasi A. Jänne · 2021 · Nature Reviews Drug Discovery · 980 citations
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
Jörge E. Cortes, Giuseppe Saglio, Hagop M. Kantarjian et al. · 2016 · Journal of Clinical Oncology · 913 citations
Purpose We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term efficacy and saf...
Reading Guide
Foundational Papers
Start with Druker et al. (2006, 3454 citations) for imatinib baseline, then Kantarjian et al. (2006, 1339 citations) for nilotinib in resistance, and Cortes et al. (2013, 1108 citations) for ponatinib context to understand second-gen evolution.
Recent Advances
Hochhaus et al. (2020 ELN recommendations, 1444 citations) for guidelines; Cortes et al. (2016 DASISION, 913 citations) and Hochhaus et al. (2016 ENESTnd, 838 citations) for long-term frontline data.
Core Methods
BCR-ABL transcript PCR for MMR (MR3.0=3-log reduction); Sokal/EUTOS scores for risk; Kaplan-Meier for PFS; mutation sequencing via Sanger NGS.
How PapersFlow Helps You Research Second-Generation Tyrosine Kinase Inhibitors
Discover & Search
Research Agent uses citationGraph on DASISION trial (Cortes et al., 2016) to map 900+ citing papers, revealing ELN updates (Hochhaus et al., 2020); exaSearch queries 'dasatinib nilotinib CML head-to-head' for 50+ trial comparisons; findSimilarPapers expands to ENESTnd follow-ups.
Analyze & Verify
Analysis Agent runs readPaperContent on DASISION PDF (Cortes et al., 2016) to extract MMR rates at 5 years; verifyResponse with CoVe cross-checks survival claims against ENESTnd (Hochhaus et al., 2016); runPythonAnalysis plots Kaplan-Meier curves from trial appendices using pandas for PFS verification; GRADE grading scores dasatinib evidence as high-quality.
Synthesize & Write
Synthesis Agent detects gaps in T315I coverage between nilotinib (Kantarjian et al., 2006) and ponatinib (Cortes et al., 2013); Writing Agent uses latexEditText for CML treatment flowchart, latexSyncCitations to integrate 10 ELN refs (Hochhaus et al., 2020), latexCompile for publication-ready review; exportMermaid generates mutation resistance diagrams.
Use Cases
"Compare 5-year MMR rates: dasatinib vs nilotinib vs imatinib in CML-CP"
Research Agent → searchPapers('DASISION ENESTnd IRIS') → runPythonAnalysis(pandas meta-analysis on response rates) → GRADE high evidence output with pooled OR=1.8 favoring second-gen TKIs.
"Generate LaTeX review on switching from imatinib to dasatinib"
Synthesis Agent → gap detection (imatinib resistance) → Writing Agent → latexEditText(draft) → latexSyncCitations(20 refs incl. Cortes 2016) → latexCompile → PDF with TKI algorithm figure.
"Find code for BCR-ABL mutation analysis in TKI trials"
Research Agent → paperExtractUrls (Hochhaus 2017) → paperFindGithubRepo (mutation simulators) → githubRepoInspect → runPythonAnalysis (reproduce variant frequency plots from Kantarjian 2006 data).
Automated Workflows
Deep Research workflow conducts systematic review of 50+ TKI papers: searchPapers → citationGraph → DeepScan (7-step verification with CoVe on MMR claims) → structured report with GRADE scores. Theorizer generates hypotheses on TKI sequencing from DASISION/ENESTnd contradictions. DeepScan analyzes cardiovascular risks: readPaperContent (Lyon 2020) → runPythonAnalysis (risk calculators) → exportCsv for meta-analysis.
Frequently Asked Questions
What defines second-generation TKIs?
Dasatinib and nilotinib target BCR-ABL with 30-fold higher potency than imatinib, effective against most resistance mutations except T315I (Kantarjian et al., 2007, 742 citations).
What are key methods for evaluation?
Phase III trials like DASISION (dasatinib vs imatinib, Cortes et al., 2016) and ENESTnd (nilotinib, Hochhaus et al., 2016) measure MMR at 12 months and 5-year PFS via PCR and Kaplan-Meier.
What are landmark papers?
DASISION 5-year results (Cortes et al., 2016, 913 citations) show dasatinib superiority; ENESTnd update (Hochhaus et al., 2016, 838 citations); ELN guidelines (Hochhaus et al., 2020, 1444 citations).
What open problems remain?
Optimal timing for TKI cessation post-deep response; managing nilotinib-induced PAOD (Lyon et al., 2020); third-line efficacy of ponatinib in mutated CML (Cortes et al., 2013).
Research Chronic Myeloid Leukemia Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Second-Generation Tyrosine Kinase Inhibitors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers